Should adjuvant weekly paclitaxel be considered less efficacious than anthracyclines plus cyclophosphamide for lower-risk patients with early-stage breast cancer? - Reply Journal Article
| Authors: | Shulman, L. N.; Berry, D. A.; Cirrincione, C. T.; Hudis, C. A.; Winer, E. P. |
| Article Title: | Should adjuvant weekly paclitaxel be considered less efficacious than anthracyclines plus cyclophosphamide for lower-risk patients with early-stage breast cancer? - Reply |
| Keywords: | cancer chemotherapy; leukemia; doxorubicin; paclitaxel; cancer patient; outcome assessment; follow up; prospective study; letter; epidermal growth factor receptor 2; cyclophosphamide; taxane derivative; trastuzumab; anthracycline; human; priority journal |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 33 |
| Issue: | 3 |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2015-01-20 |
| Start Page: | 291 |
| Language: | English |
| DOI: | 10.1200/jco.2014.59.1875 |
| PROVIDER: | scopus |
| PUBMED: | 25512457 |
| DOI/URL: | |
| Notes: | Export Date: 2 March 2015 -- Source: Scopus |
